Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113

Status: Open to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT04070768
• See Study Locations on Big Ten CRC Website

Study Contact: studies@hoosiercancer.org; (317) 921-2050.